Gerard Joseph Marek

US Patent:

20050014848, Jan 20, 2005

Filed:

Jan 30, 2004

Appl. No.:

10/769018

Inventors:

Gerard Marek - Indianapolis IN, US
Earl Giller - Madison CT, US
Tanya Ramey - New London CT, US
Megan Gibbs - Noank CT, US
Erik Wong - Portage MI, US
Robert Marshall - Mattawan MI, US

International Classification:

A61K031/135

US Classification:

514657000

Abstract:

This invention is directed to pharmaceutical compositions and methods for treating a disorder or condition selected from the group consisting of depression, anxiety disorders, phobias, avoidant personality disorder, eating disorders, chemical dependencies, Parkinson's diseases, obsessive-compulsive disorder, negative symptoms of schizophrenia, cognitive dysfunction related to schizophrenia, premenstrual syndrome, stress-induced incontinence, headache, neuropathic pain, chronic pain, urinary incontinence, post-traumatic stress disorder, chronic stress, acute stress, fibromyalgia, depression comorbid with fibromyalgia, obesity, migraine and a combination thereof in a mammal. The methods in one embodiment comprise administering to a mammal in need of treatment for the disorder or condition: (i) at least one serotonin reuptake inhibitor or pharmaceutically acceptable salt thereof; (ii) at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein the norepinephrine reuptake inhibitor is selected from the group consisting of Structure II, Structure III, and Structure IV as defined in the specification; and (iii) a pharmaceutically acceptable carrier. The pharmaceutical compositions and methods of the invention are also useful for preventing a relapse associated with one of the foregoing disorders or conditions, and for treating a symptom associated with one of the foregoing disorders or conditions, wherein the symptom is selected from the group consisting of cognitive dysfunctions and somatic complaints.

US Patent:

20050070577, Mar 31, 2005

Filed:

Jun 17, 2004

Appl. No.:

10/870127

Inventors:

Gerard Marek - East Lyme CT, US
Robert Berman - New Haven CT, US

International Classification:

A61K031/137
A61K031/445

US Classification:

514317000, 514649000

Abstract:

Novel compositions comprising a selective serotonin re-uptake inhibitor (SSRI), particularly sertraline, and a selective inhibitor for the binding of serotonin at the 5HTsite. The invention relates to the use of such compositions for treating or preventing mood disorders including depression and anxiety disorders.

US Patent:

20050250803, Nov 10, 2005

Filed:

Nov 17, 2004

Appl. No.:

10/991037

Inventors:

Paul Glue - Flemington NJ, US
Mario Saltarelli - Lake Bluff IL, US
Gerard Marek - Indianapolis IN, US

International Classification:

A61K031/4745

US Classification:

514291000, 514292000

Abstract:

This invention is directed to pharmaceutical compositions and kits comprising (i) a dopamine agonist of the formula II as described in the specification, (ii) a monoamine reuptake inhibitor or pharmaceutically acceptable salt thereof; and optionally (iii) a pharmaceutically acceptable carrier. This invention further relates to methods of treatment using those pharmaceutical compositions. Disorders or conditions that may be treated by the compositions, kits and methods of the invention include hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania, headache and a combination thereof in a mammal such as a human.

US Patent:

20060052373, Mar 9, 2006

Filed:

Nov 17, 2004

Appl. No.:

10/991046

Inventors:

Paul Glue - Flemington NJ, US
Gerard Marek - Indianapolis IN, US
Mario Saltarelli - Lake Bluff IL, US

International Classification:

A61K 31/541

US Classification:

514227500

Abstract:

The present invention relates to a pharmaceutical composition containing (i) a dopamine agonist or a pharmaceutically acceptable salt thereof, (ii) a compound of the formula I as defined in the specification, and optionally (iii) a pharmaceutically acceptable carrier, and to their medicinal use. These compositions are useful as psychotherapeutic agents.

US Patent:

20050009927, Jan 13, 2005

Filed:

Jun 3, 2004

Appl. No.:

10/860721

Inventors:

Gerard Marek - Indianapolis IN, US
Earl Giller - Madison CT, US
Tanya Ramey - New London CT, US
Megan Gibbs - Noank CT, US
Erik Wong - Portage MI, US
Robert Marshall - Mattawan MI, US

International Classification:

A61K031/137

US Classification:

514651000

Abstract:

This invention is directed in one embodiment to pharmaceutical compositions and methods for treating depression in a mammal. To a mammal in need of such treatment are administered: (i) at least one serotonin reuptake inhibitor or pharmaceutically acceptable salt thereof; and (ii) at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein the norepinephrine reuptake inhibitor is selected from the group consisting of Structure II, Structure III, and Structure IV as defined herein.

US Patent:

20220370468, Nov 24, 2022

Filed:

Jul 22, 2020

Appl. No.:

17/627993

Inventors:

- Northbrook IL, US
Gerard Marek - Vernon Hills IL, US
Katherine Tracy - Sonoma CA, US
Mary Beth Blauwet - Lindenhurst IL, US
Michael Smith - Ann Arbor MI, US
Mark Walzer - River Forest IL, US
Marci English - Clarendon Hills IL, US

International Classification:

A61K 31/5377
A61P 25/20

Abstract:

Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising: a) identifying a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Provided herein in some embodiments are methods of treating a sleep disorder associated with pain in a patient in need thereof, comprising: a) selecting a patient having a sleep disorder associated with pain; and b) administering to the patient identified in step a) a compound of Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, the sleep disorder is selected from the group consisting of difficulty with falling asleep; restlessness of sleep; difficulty getting comfortable; difficulty staying asleep; degree of deep sleep; degree of being rested when waking up for the day; difficulty with beginning the day; and degree of having enough sleep during the previous night. In some embodiments, the sleep disorder is associated with pain selected from the group consisting of fibromyalgia, neuropathic pain, osteoarthritis, and visceral pain. In some more particular embodiments, the visceral pain is selected from the group consisting of IBS associated pain and bladder pain.